Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells
出版年份 2016 全文链接
标题
Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells
作者
关键词
MUC1, CAR-T therapy, solid tumor, seminal vesicle cancer
出版物
Science China-Life Sciences
Volume 59, Issue 4, Pages 386-397
出版商
Springer Nature
发表日期
2016-03-10
DOI
10.1007/s11427-016-5024-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer
- (2015) Victoria Hillerdal et al. BIODRUGS
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
- (2015) S. L. Maude et al. BLOOD
- TRUCKs: the fourth generation of CARs
- (2015) Markus Chmielewski et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors
- (2015) Hinrich Abken Immunotherapy
- Chimeric Antigen Receptors With Mutated IgG4 Fc Spacer Avoid Fc Receptor Binding and Improve T Cell Persistence and Antitumor Efficacy
- (2015) Mahesh Jonnalagadda et al. MOLECULAR THERAPY
- The Clinical Significance of Hypoxia in Human Cancers
- (2015) Neesha Dhani et al. SEMINARS IN NUCLEAR MEDICINE
- The Breast Cancer-Associated Glycoforms of MUC1, MUC1-Tn and sialyl-Tn, Are Expressed in COSMC Wild-Type Cells and Bind the C-Type Lectin MGL
- (2015) Richard Beatson et al. PLoS One
- Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition
- (2015) Maud Condomines et al. PLoS One
- CD28z CARs and Armored CARs
- (2014) Hollie J. Pegram et al. CANCER JOURNAL
- Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor
- (2014) S. Wilkie et al. JOURNAL OF IMMUNOLOGY
- IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia
- (2014) H J Pegram et al. LEUKEMIA
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Designing a recombinant chimeric construct contain MUC1 and HER2 extracellular domain for prediagnostic breast cancer
- (2014) Elaheh Gheybi et al. TUMOR BIOLOGY
- T Cell Receptor-Engineered T Cells to Treat Solid Tumors: T Cell Processing Toward Optimal T Cell Fitness
- (2014) Cor H.J. Lamers et al. Human Gene Therapy Methods
- Chimeric antigen receptor T-cell therapy for ALL
- (2014) S. L. Maude et al. Hematology-American Society of Hematology Education Program
- Toxicity management for patients receiving novel T-cell engaging therapies
- (2013) David M. Barrett et al. CURRENT OPINION IN PEDIATRICS
- Chimeric Antigen Receptor Therapy for Chronic Lymphocytic Leukemia
- (2013) Marco L. Davila et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma
- (2013) Markus Chmielewski et al. IMMUNOLOGICAL REVIEWS
- Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells
- (2013) Michael C. Jensen et al. IMMUNOLOGICAL REVIEWS
- Potential for novel MUC1 glycopeptide-specific antibody in passive cancer immunotherapy
- (2013) Caroline B. Madsen et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- Chimeric antigen receptor modified T cell therapy for B cell malignancies
- (2013) Cameron J. Turtle INTERNATIONAL JOURNAL OF HEMATOLOGY
- Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
- (2013) Cor HJ Lamers et al. MOLECULAR THERAPY
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning
- (2012) H. J. Pegram et al. BLOOD
- Suppression, subversion and escape: the role of regulatory T cells in cancer progression
- (2012) K. Oleinika et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice
- (2012) D. Chinnasamy et al. CLINICAL CANCER RESEARCH
- MUC1 immunotherapy is here to stay
- (2012) Takashi Kimura et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- CD28 Costimulation Impairs the Efficacy of a Redirected T-cell Antitumor Attack in the Presence of Regulatory T cells Which Can Be Overcome by Preventing Lck Activation
- (2011) David M Kofler et al. MOLECULAR THERAPY
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemotactic antiviral cytokines promote infectious apical entry of human adenovirus into polarized epithelial cells
- (2011) Verena Lütschg et al. Nature Communications
- MUC1 immunotherapy
- (2010) Richard E Beatson et al. Immunotherapy
- Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b
- (2010) John A. Craddock et al. JOURNAL OF IMMUNOTHERAPY
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- The membrane-bound mucins: From cell signalling to transcriptional regulation and expression in epithelial cancers
- (2009) Nicolas Jonckheere et al. BIOCHIMIE
- CAR Mechanics: Driving T Cells into the MUC of Cancer
- (2009) J. Maher et al. CANCER RESEARCH
- Strategies used for MUC1 immunotherapy: preclinical studies
- (2008) Choon-Kit Tang et al. Expert Review of Vaccines
- Strategies used for MUC1 immunotherapy: human clinical studies
- (2008) Choon-Kit Tang et al. Expert Review of Vaccines
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search